Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or ...
There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and ...
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each ...
According to CMS estimates, passage of the rule would open access to the weight-loss medications to 3.4 million potential new ...
The anti-obesity drug market has expanded significantly in recent years, with the FDA approving a new class of weekly injectables like Novo Nordisk's Wegovy and Eli Lilly's Zepbound to treat obesity.
Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback